{
  "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
  "docSlug": "adb5c4514a6016378ffb63c7d4422971",
  "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
  "authorId": "tcr2-therapeutics",
  "authorName": "TCR2 Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 34,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/31",
  "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
  "deckJsonHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5.json",
  "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.85,
        "y": 0.0028
      },
      "kind": "callout",
      "text": "All patients in complete response at 6 months remain clinically well without receiving any systemic anticancer therapy other than CTX110",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abd0bbb9-cb89-42c2-9bf5-49c1a6f81205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.42,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Swimmer plot of patient responses over time",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56f4243e-1c9e-465d-945c-49a2daae3d71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.15,
        "y": 0.0032
      },
      "kind": "list",
      "text": "Patients had 2 doses from one manufacturing run",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "100c766f-9609-4509-b024-13da9eb4e882",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.15,
        "y": 0.0062
      },
      "kind": "list",
      "text": "Patients eligible for a redosing based on Phase 2 protocols",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14850d4d-64e1-4189-8c07-7d812e5a3c8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.42,
        "y": 0.0065
      },
      "kind": "list",
      "text": "CRISPR Highlights: Evaluated safety and efficacy of CTX110... Option for 2nd CTX110 infusion... 5 out of 8 patients receiving a second dose saw an improved response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ccb9d83-fcbd-4a3d-b551-7b2e97a45a8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.15,
        "y": 0.0045
      },
      "kind": "list",
      "text": "Patients had 3 doses from one manufacturing run",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5edcc00b-5b9c-4666-a202-e66d74f062e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.04,
        "y": 0.0032
      },
      "kind": "metric",
      "text": "100%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b24b80f-da5b-49f8-afac-3b82c617c88a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.04,
        "y": 0.0045
      },
      "kind": "metric",
      "text": "97%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9cf6cea-b2ec-428d-9081-c447b495975d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.04,
        "y": 0.0062
      },
      "kind": "metric",
      "text": "46%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6f1abd7-e675-4efb-a5d9-fcac83acad10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.04,
        "y": 0.0018
      },
      "kind": "paragraph",
      "text": "Based on gavo-cel Phase 1 manufacturing experience:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c691891d-c963-4a53-a2ce-58c89b5956c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.42,
        "y": 0.008199999999999999
      },
      "kind": "source-note",
      "text": "Source: CRISPR public materials, Trial: NCT04035434 (CARBON)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "477de729-d77c-4afa-a857-4dccab4cabd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Redosing Allowed from 12 Weeks, Could Deepen Patient Responses",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5247252-122c-445a-861a-54ddbb399e91",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "24074dc4-7d1d-4598-8fd2-9b4dc0d90c49",
      "evidence": "chart/bar-horizontal: Swimmer plot of patient responses over time",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5b317713-b24e-4c4c-844c-489f547f7280",
      "evidence": "list/bullet: CRISPR Highlights: Evaluated safety and efficacy of CTX110...",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}